Baird lowered the firm’s price target on Cogent Biosciences (COGT) to $7 from $8 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results and the first major readout for its pivotal SUMMIT data in NonAdvSm is on track for July.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Cogent Biosciences Advances with Promising Clinical Trials
- Cogent Biosciences reports Q1 net loss $72M
- Cogent Biosciences appoints Ray Frost as SVP, Market Access
- Cogent to present preclinical data from pipeline programs at AACR meeting
- JPMorgan healthcare analysts hold an analyst/industry conference call